Patents by Inventor Wendi YANG

Wendi YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240134939
    Abstract: A deep learning-based method for fusing multi-source urban energy data and a storage medium are provided to perform data fusion on multi-source urban energy data found in big data and perform multi-scale and multimodal information fusion by using a cross-modal transformer, thereby implementing cross-modal mutual fusion of multi-source heterogeneous types of data to obtain a fused feature for prediction of a quantity of energy that will be used in the future and a quantity of energy that needs to be produced. The present disclosure proposes a multi-scale cooperative multimodal transformer architecture to enhance an effect of representation learned from an unaligned multimodal sequence. Not only there is a higher degree of correlation in multi-source urban energy data fusion, but also a system becomes more lightweight.
    Type: Application
    Filed: December 4, 2022
    Publication date: April 25, 2024
    Applicant: STATE GRID JIANGSU ELECTRIC POWER CO., LTD NANJING POWER SUPPLY COMPANY
    Inventors: Zhengyi ZHU, Honghua XU, Weiya ZHANG, Long LIANG, Jinjie MA, Hengjun ZHOU, Wendi WANG, Xin QIAN, Linqing YANG
  • Publication number: 20230235011
    Abstract: A Fc-CD80 fusion protein has a CD80 extracellular domain (ECD) linked to a C-terminal of an immunoglobulin Fc domain. The Fc-CD80 fusion protein can be used for the preparation of a conjugate, the conjugate including the Fc-CD80 fusion protein as a first component, and a second component containing a second effector molecule, the second component being located at an N-terminal of the first component. In addition, a conjugate including the Fc-CD80 fusion protein, a pharmaceutical composition including the Fc-CD80 fusion protein and/or the conjugate are effective for the treatment or prevention of cancerous diseases in individuals.
    Type: Application
    Filed: May 25, 2021
    Publication date: July 27, 2023
    Inventors: Pinliang HU, Jing ZOU, Weidong HONG, Yun HE, Lingyun SONG, Wendi YANG
  • Patent number: 11667704
    Abstract: The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 6, 2023
    Assignees: BEIJING BEYOND BIOTECHNOLOGY CO., LTD, HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Pinliang Hu, Jing Zou, Weidong Hong, Yun He, Jie Bai, Lingyun Song, Wendi Yang, Zhijian Lv, Shaoyun Xiang
  • Publication number: 20220106389
    Abstract: The present invention provides a multi-targeting fusion protein that blocks the growth of vascular endothelial cells and activates T cells, which comprises (i) a vascular endothelial cell growth inhibitory domain; (ii) an immunoglobulin Fc domain; and (iii) CD80 extracellular domain (ECD). The present invention also provides a polynucleotide encoding the multi-targeting fusion protein, a vector containing the polynucleotide, a host cell comprising the polynucleotide or the vector, and pharmaceutical composition comprising the multi-targeting fusion protein and an anti-PD-1 antibody. The multi-targeting fusion protein and pharmaceutical composition of the present invention can treat or prevent cancerous diseases in individuals.
    Type: Application
    Filed: January 9, 2020
    Publication date: April 7, 2022
    Inventors: Pinliang Hu, Jing Zou, Weidong Hong, Yun He, Jie Bai, Lingyun Song, Wendi Yang, Guimin Zhang, Lili Zhao, Zhong Liu, Zhenyu Li, Zhongsong Zhu
  • Publication number: 20210261654
    Abstract: The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
    Type: Application
    Filed: November 6, 2018
    Publication date: August 26, 2021
    Inventors: Pinliang HU, Jing ZOU, Weidong HONG, Yun HE, Jie BAI, Lingyun SONG, Wendi YANG, Zhijian LV, Shaoyun XIANG